Preview Mode Links will not work in preview mode

Dec 17, 2021

Featuring an interview with Dr Gregory Riely, including the following topics:

  • EGFR exon 20 insertions in non-small cell lung cancer (NSCLC) (0:00)
  • Antitumor activity, mechanism of action and tolerability of mobocertinib for patients with NSCLC and EGFR exon 20 mutations (4:59)
  • Antitumor activity and tolerability of the EGFR-MET bispecific antibody amivantamab (11:05)
  • Considerations for using real-world data to create synthetic control arms for clinical trials (17:48)
  • Novel investigational agents for and future management of NSCLC with EGFR exon 20 insertions (23:48)

CME information and select publications